PEN Quote, Financials, Valuation and Earnings

Globus Medical has a net margin of 9.81% compared to Penumbra's net margin of 8.28%. Penumbra's return on equity of 3% beat Globus Medical's return on equity of 2.27%.

Penumbra has a consensus price target of $254.60, signalling upside risk potential of 7.2%. On the other hand Globus Medical has an analysts' consensus of $93.85 which suggests that it could grow by 13.82%. Given that Globus Medical has higher upside potential than Penumbra, analysts believe Globus Medical is more attractive than Penumbra.

Penumbra has a beta of 0.521, which suggesting that the stock is 47.872% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.188, suggesting its more volatile than the S&P 500 by 18.849%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $301M, which are smaller than Globus Medical quarterly revenues of $625.7M. Penumbra's net income of $29.5M is lower than Globus Medical's net income of $51.8M. Notably, Penumbra's price-to-earnings ratio is 281.36x while Globus Medical's PE ratio is 123.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.14x versus 4.58x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Inari Medical has a net margin of 9.81% compared to Penumbra's net margin of -11.97%. Penumbra's return on equity of 3% beat Inari Medical's return on equity of -17.68%.

Penumbra has a consensus price target of $254.60, signalling upside risk potential of 7.2%. On the other hand Inari Medical has an analysts' consensus of $64.38 which suggests that it could grow by 33.79%. Given that Inari Medical has higher upside potential than Penumbra, analysts believe Inari Medical is more attractive than Penumbra.

Penumbra has a beta of 0.521, which suggesting that the stock is 47.872% less volatile than S&P 500. In comparison Inari Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inari Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. Inari Medical pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $301M, which are larger than Inari Medical quarterly revenues of $153.4M. Penumbra's net income of $29.5M is higher than Inari Medical's net income of -$18.4M. Notably, Penumbra's price-to-earnings ratio is 281.36x while Inari Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.14x versus 5.03x for Inari Medical. Usually stocks with elevated PS ratios are considered overvalued.

QuidelOrtho has a net margin of 9.81% compared to Penumbra's net margin of -2.74%. Penumbra's return on equity of 3% beat QuidelOrtho's return on equity of -47.52%.

Penumbra has a consensus price target of $254.60, signalling upside risk potential of 7.2%. On the other hand QuidelOrtho has an analysts' consensus of $50.29 which suggests that it could grow by 9.61%. Given that QuidelOrtho has higher upside potential than Penumbra, analysts believe QuidelOrtho is more attractive than Penumbra.

Penumbra has a beta of 0.521, which suggesting that the stock is 47.872% less volatile than S&P 500. In comparison QuidelOrtho has a beta of 0.079, suggesting its less volatile than the S&P 500 by 92.104%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. QuidelOrtho offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Penumbra pays -- of its earnings as a dividend. QuidelOrtho pays out -- of its earnings as a dividend.

Penumbra quarterly revenues are $301M, which are smaller than QuidelOrtho quarterly revenues of $727.1M. Penumbra's net income of $29.5M is higher than QuidelOrtho's net income of -$19.9M. Notably, Penumbra's price-to-earnings ratio is 281.36x while QuidelOrtho's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.14x versus 1.11x for QuidelOrtho. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 9.81% compared to Penumbra's net margin of 25.43%. Penumbra's return on equity of 3% beat ResMed's return on equity of 23.76%.

Penumbra has a consensus price target of $254.60, signalling upside risk potential of 7.2%. On the other hand ResMed has an analysts' consensus of -- which suggests that it could grow by 10.65%. Given that ResMed has higher upside potential than Penumbra, analysts believe ResMed is more attractive than Penumbra.

Penumbra has a beta of 0.521, which suggesting that the stock is 47.872% less volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.

Penumbra has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.87% to investors and pays a quarterly dividend of $0.53 per share. Penumbra pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Penumbra quarterly revenues are $301M, which are smaller than ResMed quarterly revenues of $1.2B. Penumbra's net income of $29.5M is lower than ResMed's net income of $311.4M. Notably, Penumbra's price-to-earnings ratio is 281.36x while ResMed's PE ratio is 30.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Penumbra is 8.14x versus 7.11x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.